Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer

1 rich Libsyn https://www.libsyn.com 90 600 Black patients with ES-SCLC get less chemo, CTCs may guide breast cancer treatment, and new FDA approvals for neuroblastoma and prostate cancer Blood &amp; Cancer news stories: Black patients with ES-SCLC get less chemo but have better survival: https://bit.ly/33Rb5eB Should CTCs guide treatment choice in HR+, HER2– breast cancer?: https://bit.ly/3gn6shc New drug approved for relapsed/refractory neuroblastoma: https://bit.ly/2VMpvIy FDA approves first agent for PSMA-PET imaging in prostate cancer: https://bit.ly/36TAaY7 Contact Blood &amp; Cancer at podcasts@mdedge.com. Blood & Cancer https://www.mdedge.com/podcasts/blood-cancer <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/17098322/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/984545/" height="90" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/item/17098322